What is the recommended dosing schedule for nab‑paclitaxel and carboplatin, including adjustments for renal impairment, neutropenia, thrombocytopenia, and peripheral neuropathy?

Recommended Dosing Schedule for Nab-Paclitaxel and Carboplatin

For ovarian cancer, administer nab-paclitaxel 100 mg/m² IV on days 1,8, and 15 combined with carboplatin AUC 5-6 IV on day 1, repeated every 3 weeks for 6 cycles. This weekly nab-paclitaxel schedule is not explicitly listed in NCCN guidelines for ovarian cancer, but the standard paclitaxel/carboplatin regimens provide the framework for dosing 1.

Standard Dosing Regimens

The NCCN guidelines establish several Category 1 paclitaxel/carboplatin options for ovarian cancer 1:

• Standard 3-weekly: Paclitaxel 175 mg/m² IV over 3 hours followed by carboplatin AUC 5-6 IV over 1 hour on Day 1, repeated every 3 weeks × 6 cycles
• Dose-dense weekly: Paclitaxel 80 mg/m² IV over 1 hour on Days 1,8, and 15 followed by carboplatin AUC 5-6 IV over 1 hour on Day 1, repeated every 3 weeks × 6 cycles
• Weekly low-dose: Paclitaxel 60 mg/m² IV over 1 hour followed by carboplatin AUC 2 IV over 30 minutes, weekly for 18 weeks

For nab-paclitaxel specifically in NSCLC (which provides dosing guidance), the FDA-approved regimen is nab-paclitaxel 100 mg/m² on days 1,8, and 15 with carboplatin AUC 6 on day 1 every 3 weeks 2, 3.

Dose Adjustments for Toxicity

Neutropenia

• Hold treatment if neutrophil count <1,500 cells/mm³ for solid tumors 2
• Reduce dose by 20% for subsequent cycles if severe neutropenia (neutrophils <500 cells/mm³ for ≥1 week) occurs 2
• Monitor CBC with platelets before each cycle and at least every 2-3 cycles during treatment 1

Thrombocytopenia

• Hold treatment if platelet count <100,000 cells/mm³ 2
• Consider dose reduction if severe thrombocytopenia (<50,000 cells/mm³) develops
• Weekly nab-paclitaxel regimens show higher rates of grade 3-4 thrombocytopenia (21-29%) compared to tri-weekly schedules 3, 4

Peripheral Neuropathy

• Reduce dose by 20% for subsequent cycles if severe peripheral neuropathy (Grade 3-4) develops 2
• Weekly nab-paclitaxel demonstrates significantly less peripheral neuropathy than solvent-based paclitaxel: grade ≥3 neuropathy occurs in only 2-3% with nab-paclitaxel versus 12-13% with standard paclitaxel 3, 5
• If Grade 2 neuropathy develops, consider dose reduction or treatment delay until improvement to Grade 1 or baseline

Renal Impairment and Carboplatin Dosing

The NCCN guidelines note that "due to changes in creatinine methodology, changes regarding carboplatin dosing can be considered" and reference the FDA carboplatin dosing statement 1.

For carboplatin dose calculation:

• Use the Calvert formula: Dose (mg) = Target AUC × (GFR + 25)
• Cap the calculated GFR at 125 mL/min to avoid overdosing in patients with normal/high renal function
• For significant renal impairment (CrCl <60 mL/min), reduce carboplatin AUC or consider alternative regimens

Hepatic Impairment Adjustments

The FDA label provides specific dose reductions for hepatic impairment with 24-hour infusions 2:

For 24-hour infusion (baseline 135 mg/m²):

• Transaminases <2× ULN and bilirubin ≤1.5 mg/dL: 135 mg/m²
• Transaminases 2-10× ULN and bilirubin ≤1.5 mg/dL: 100 mg/m²
• Transaminases <10× ULN and bilirubin 1.6-7.5 mg/dL: 50 mg/m²
• Transaminases ≥10× ULN or bilirubin >7.5 mg/dL: Not recommended

For 3-hour infusion (baseline 175 mg/m²):

• Transaminases <10× ULN and bilirubin ≤1.25× ULN: 175 mg/m²
• Transaminases <10× ULN and bilirubin 1.26-2× ULN: 135 mg/m²
• Transaminases <10× ULN and bilirubin 2.01-5× ULN: 90 mg/m²
• Transaminases ≥10× ULN or bilirubin >5× ULN: Not recommended

Important Clinical Considerations

Weekly versus tri-weekly schedules: The dose-dense weekly paclitaxel regimen (80 mg/m² days 1,8,15) shows likely slight improvement in PFS (HR 0.89) but no OS benefit compared to tri-weekly dosing in ovarian cancer 6. However, weekly schedules increase grade 3-4 anemia (RR 1.57) and treatment discontinuations 6.

Elderly patients (≥70 years): In NSCLC data, nab-paclitaxel 100 mg/m² weekly with carboplatin AUC 6 showed superior efficacy in elderly patients with squamous histology, achieving 46% ORR versus 20% with standard paclitaxel and median OS of 16.9 versus 8.6 months 4.

Premedication: Unlike solvent-based paclitaxel, nab-paclitaxel does not require routine corticosteroid premedication, reducing infection risk and hyperglycemia 3, 5. Standard antiemetics for carboplatin remain necessary.

Monitoring schedule: Perform CBC before each cycle, CA-125 or tumor markers prior to each cycle, and physical/pelvic exams every 2-3 cycles 1.